Zilovertamab vedotin (VLS-101) is an experimental cancer therapy that targets ROR1, a protein found in many blood and solid tumors. It combines a ROR1-specific antibody with MMAE, a strong cancer-killing drug. This approach delivers the drug directly to cancer cells while sparing healthy tissues.
Key Features
- Targeted Therapy: Binds to ROR1, a protein overexpressed in cancers like chronic lymphocytic leukemia (CLL), mantle cell lymphoma (MCL), and some solid tumors.
- Mechanism of Action: Enters cancer cells after attaching to ROR1 and releases MMAE, which destroys the cell’s microtubules, stopping its growth.
- Focused Treatment: Protects healthy cells by targeting cancer-specific proteins.
Clinical Progress
Researchers tested zilovertamab vedotin in people with cancers like CLL, MCL, and diffuse large B-cell lymphoma (DLBCL). The therapy showed promise in shrinking tumors and caused manageable side effects.
Applications
- Blood Cancers: Treats ROR1-positive cancers such as CLL, MCL, and DLBCL.
- Solid Tumors: Explores effectiveness in cancers like breast and lung cancer.
- Cancer Drug Development: Advances targeted therapy for ROR1-related cancers.
Zilovertamab vedotin offers a new way to treat cancer with precision, focusing on killing tumors while limiting damage to the rest of the body.
AxisPharm offers 5000+ PEG Linkers with high purity. Different kinds of PEG Reagents may be available by custom synthesis.